



**NATURAL
BIOCON**

INDIA LISTED

www.naturalbiocon.com

079 46005570

info@naturalbiocon.com

Regd. Office :

A-1007, Sankalp Iconic Tower,
Opp. Vikram Nagar, Iscon Temple Cross Road,
S.G. Highway, Ahmedabad 380054, Gujarat, India

GST NO : 24AAACN6842K1Z0

CIN : L24289GJ1992PLC018210

02nd May, 2023

To, The General Manager Corporation Relationship Department BSE Limited P.J Towers, Dalal Street Mumbai - 400001 Script Code: 543207	To, The Secretary The Calcutta Stock Exchange Ltd. 7, Lyons Range Kolkata - 700 001 Scrip Code: 24151
---	--

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on (Tuesday) May 02, 2023.

Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their meeting held on today i.e., Tuesday, May 02, 2023 at the Registered Office of the Company inter-alia has, considered and approved Standalone Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023, along with Statement of Profit & Loss, Statement of Assets & Liabilities and the Statement of Cash Flow, for the financial year ended March 31, 2023, in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations, along with the Auditors' Reports thereon.

These results have been duly reviewed by the Audit Committee and Audited by CA Sanket Shah, Chartered Accountants (M. No.: 150873), Statutory Auditors of the Company.

(The copies of the aforesaid Standalone Financial Results along with the Auditors' Reports thereon and Declaration on Unmodified Opinion on the Audit Report, on standalone basis, are enclosed herewith.)

The Board Meeting commenced at 04.00 p.m. and concluded at 6.00 p.m.

Please take the same on record.

Thanking You

Yours faithfully,

Natural Biocon (India) Ltd

Manish Patel

Director/CFO

DIN: 09289884

For Natural Biocon (India) Limited

Director / Authorised Signatory



NATURAL
BIOCON

INDIA LIMITED

www.naturalbiocon.com

079 46005570

info@naturalbiocon.com

Regd. Office :
A-1007, Sankalp Iconic Tower,
Opp. Vikram Nagar, Iscon Temple Cross Road,
S.G. Highway, Ahmedabad 380054, Gujarat, India

GST NO : 24AAACN6841K1ZD

CIN : L24299GJ1992PLC018210

02nd May, 2023

To, The General Manager Corporation Relationship Department BSE Limited P.J Towers, Dalal Street Mumbai - 400001 Script Code: 543207	To, The Secretary The Calcutta Stock Exchange Ltd. 7, Lyons Range Kolkata - 700 001 Scrip Code: 24151
---	--

**Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to above, we hereby state that the statutory Auditor of the Company Mr. Sanket Shah have issued an Audit Report with unmodified opinion on the Standalone Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2023 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking You

Yours faithfully,

Natural Biocon (India) Ltd

For, Natural Biocon (India) Limited

Manish Patel
Director/CFO **Director / Authorised Signatory**
DIN: 09289884

Encl. As Above

Natural Biocon (India) Limited

Reg. Office: 1007, Sankalp Iconic, Opp. Vikram Nagar, Iscon Temple Cross Road, Ahmedabad-380054

Email ID: naturalbioconindia@gmail.com, CIN: L24299GJ1992PLC018210

Financial results by company					
PART I		(Rs. in Lakhs)			
Statement of Standalone Audited Results for the Quarter and Year Ended 31/03/2023					
Particulars	Quarter Ended			Year Ended	
	(31/03/2023)	(31/12/2022)	(31/03/2022)	(31/03/2023)	(31/03/2022)
(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
	(Refer Note 4)		(Refer Note 4)		
1 Revenue from Operation	86.47	38.96	24.02	125.43	48.18
Other income	0.00	0.00	0.00	0.00	0.00
Total Revenue (I + II)	86.47	38.96	24.02	125.43	48.18
2 Expenses					
(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	142.03	31.96	25.59	173.99	28.75
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(86.10)	0.00	0.00	(86.10)	0.00
(d) Employee benefits expense	4.02	0.51	0.09	4.53	2.54
(e) Finance Cost	0.12	0.00	0.06	0.12	0.09
(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00
(g) Other expenses	8.09	0.10	2.01	8.19	8.02
Total expenses	68.16	32.57	27.75	100.73	39.40
3 Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)	18.31	6.39	(3.73)	24.70	8.79
4 Exceptional items	0.00	0.00	0.00	0.00	0.00
5 Profit / (Loss) before extraordinary items and tax (V - VI)	18.31	6.39	(3.73)	24.70	8.79
6 Tax expense - Provision for taxation					
Current Tax - Provision for taxation	5.08	1.71	0.57	6.79	2.20
Deferred Tax					
7 Net Profit / (Loss) for the period	13.23	4.68	(4.30)	17.91	6.59
8 Other Comprehensive Income/(Loss) (net of tax)	0.00	0.00	0.00	0.00	0.00
9 Total Comprehensive Income/(Loss) for the period	13.23	4.68	(4.30)	17.91	6.59
10 Paid up Equity Share Capital (Face value of Rs. 10/- each)	1137.28	1137.28	1137.28	1137.28	1137.28
11 Earnings per equity share:					
(1) Basic	0.01	0.00	(0.00)	0.02	0.01
(2) Diluted	0.01	0.00	(0.00)	0.02	0.01

Notes:

- The Audited Financial Results for the Quarter and Year ended 31st March, 2023, have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors at their respective meetings held on May 02, 2023. The Statutory Auditors of the Company have carried out an audit for the year ended March 31, 2023 and the Statutory Auditors have expressed an unmodified audit opinion thereon.

Natural Biocon (India) Limited

Reg, Office: 1007, Sankalp Iconic, Opp. Vikram Nagar, Iscon Temple Cross Road, Ahmedabad-380054

Email ID: naturalbioconindia@gmail.com, CIN: L24299GJ1992PLC018210

- 2 The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
- 3 The Audited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- 4 The Figures of the quarter ended 31st March, 2023 are the balancing figures between Audited Figures in respect of the Full Financial year and the published year to date figures up to third quarter of the relevant financial year.
- 5 The Company is presently dealing in only one segment.
- 6 Figures relating to the previous year / period have been regrouped / rearranged, wherever necessary, to make them comparable with those of the current year / period.
- 7 This communication is in compliance with the SEBI (Listing Obligations & Requirement) Regulations, 2015.

Date: 02.05.2023

Place: Ahmedabad

By Order of the Board of Directors

For Natural Biocon (India) Limited

For, NATURAL BIOCON (INDIA) LIMITED.

Manish Patel

Director/CFO

DIN: 09289884


DIRECTOR


Statement Of Assets and Liability

(Rs. In Lacs)

Particulars	As at 31st March 2023	As at 31st March 2022
	Audited	Audited
A) Assets		
Non Current Assets		
Property Plant and Equipment	0.69	0.69
Capital Work In Progress	328.99	328.99
Other Intangible Assets	-	-
Intangible assets under Development	-	-
Financial Assets		
i) Investment	-	-
ii) Loan	806.95	806.95
iii) Other Financial Assets	-	-
Deferred Tax Assets (net)	-	-
Other non current Assets	-	-
Total Non Current Assets	1,136.63	-
Current Assets		
Inventories	91.63	5.52
Financial Assets		
i) Trade Receivable	62.82	49.24
ii) Cash and Cash Equivalents	40.02	20.93
iii) Bank Balance other than (ii)above	0.08	-
iv) Loans and Advances	20.57	17.40
iv) Other Financial Assets	-	-
Other Current Assets	-	-
Total Current Assets	215.12	93.10
Total Assets	1,351.75	-
B) Equity and Liabilities		
Equity Share Capital	1,137.28	1,137.28
Other Equity	85.75	67.84
Total Equity	1,223.03	1,205.12
Non Current Liabilities		
Financial Liabilities		
i) Borrowings	-	-
Deferred Tax Liabilities	-	-
Total Non Current Liabilities	1,223.03	1,205.12
Current Liabilities		
Financial Liabilities		
i) Borrowings	15.44	17.30
ii) Trade Payables	101.58	2.25
iii) Other Financial Liabilities	-	-
Provisions	9.96	2.77
Other Current Liabilities	1.74	2.29
Total Current Liabilities	128.72	24.61
Total Equity and Liabilities	1,351.75	1,229.73

Date: 02.05.2023
Place: Ahmedabad


By Order of the Board of Directors
For, NATURAL BIOCON (INDIA) Limited



DIRECTOR

Manish Patel
Director/CFO
DIN: 09289884

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2023

Particulars	For the period ended on 31.03.2023	For the period ended on 31.03.2022
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	24.70	8.79
Adjustments for:		
Depreciation	0.00	0.00
Preliminary Exps. Written off	0.00	0.00
Finance Cost	0.00	0.00
Operating Profit before Working Capital Changes	24.70	8.79
Movements in Working Capital :		
Decrease / (Increase) in Inventories	-86.10	0.00
Decrease / (Increase) in Sundry Debtors	-13.57	2.58
Decrease / (Increase) in Loans and Advances	0.00	-77.07
Decrease / (Increase) in Current Assets	-3.17	100.28
(Decrease) / Increase in Trade Payables	99.33	2.25
(Decrease) / Increase in Short Term Provisions	7.18	2.20
(Decrease) / Increase in Current Liabilities	-0.54	-18.21
(Decrease) / Increase in Other Current Liabilities	0.00	-0.71
Cash (used in) / generated from operations	27.83	20.10
Direct Taxes Paid (net of refunds)	6.79	2.20
Net cash (used in) / generated from operating activities (A)	21.04	17.90
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Purchase) of Fixed Assets	0.00	-0.69
Sale / Disposal of Fixed Assets	0.00	0.00
Profit on sale of Investment / Assets	0.00	0.00
Net cash (used in) / generated from investing activities (B)	0.00	-0.69
C. CASH FLOW FROM FINANCING ACTIVITIES		
(Repayment) / Proceeds From Long Term Borrowings	-1.86	0.00
(Repayment) / Proceeds From Short Term Borrowings	0.00	0.00
Repayment / (Proceeds) From Long Term Loans & Advances	0.00	0.00
Proceeds from Issue of Shares	0.00	0.00
Interest Expense	0.00	0.00
Dividend	0.00	0.00
Dividend Distribution Tax	0.00	0.00
Net cash (used in) / generated from financing activities (C)	(1.86)	-
D.NET INCREASE IN CASH AND CASH EQUIVALENTS (D)=(A+B)	19.18	17.21
Cash and cash equivalents at the beginning of the year	20.93	3.72
Cash and cash equivalents at the end of the year	40.11	20.93
Components of cash and cash equivalents		
Cash and cheques on hand	40.02	20.49
With Scheduled Banks		
- in Current Account	0.09	0.44
- in Term Deposit Accounts		
	40.11	20.93
Date: 02.05.2023		
Place: Ahmedabad		
	By Order of the Board of Directors For Natural Biocon (India) Limited For, NATURAL BIOCON (INDIA) LIMITED	
	 Manish Patel Director/CFO DIN: 09289884 DIRECTOR	



Auditor's Report on Quarterly Financial Results and Year to date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

To,
The Board of Directors,
Natural Biocon (India) Limited

Report on audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone annual financial results of **Natural Biocon (India) Limited** (the company) for the quarter and financial year ended 31st March, 2023, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the period from 01st April, 2022 to 31st March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited interim condensed financial statement for the year ended March 31, 2023. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in



Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit



evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Others Matters

The figures for the quarter ended March 31, 2023, as reported in these financial results are the balancing figures between audited figures in respect of respective full financial year and the figures up to December 31, 2022.

For and on behalf of,
Sanket Shah
Chartered Accountants
M. No. 150873
UDIN: 23150873BGSDMY7390

Date: 02.05.2023
Place: Ahmedabad

